These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 15261379)

  • 1. [Monoclonal antibodies and therapeutics].
    Desgranges C
    Pathol Biol (Paris); 2004 Jul; 52(6):351-64. PubMed ID: 15261379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered antibodies take center stage.
    Huston JS; George AJ
    Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress in biomolecular engineering.
    Ryu DD; Nam DH
    Biotechnol Prog; 2000; 16(1):2-16. PubMed ID: 10662483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressive monoclonal antibodies: current and next generation.
    Focosi D; Maggi F; Pistello M; Boggi U; Scatena F
    Clin Microbiol Infect; 2011 Dec; 17(12):1759-68. PubMed ID: 21995285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
    Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
    Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies and fusion proteins in medicine.
    Liossis SN; Tsokos GC
    J Allergy Clin Immunol; 2005 Oct; 116(4):721-9; quiz 730. PubMed ID: 16210042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of humanized antibodies as cancer therapeutics.
    Qu Z; Griffiths GL; Wegener WA; Chang CH; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM
    Methods; 2005 May; 36(1):84-95. PubMed ID: 15848077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes].
    Siberil S; Dutertre CA; Boix C; Teillaud JL
    Transfus Clin Biol; 2005 Jun; 12(2):114-22. PubMed ID: 15907389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Progression and direction of humanized antibody research].
    Lin Y; Yan XY
    Sheng Wu Gong Cheng Xue Bao; 2004 Jan; 20(1):1-5. PubMed ID: 16108479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies and genetically engineered related molecules: production and purification.
    Roque AC; Lowe CR; Taipa MA
    Biotechnol Prog; 2004; 20(3):639-54. PubMed ID: 15176864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered affinity proteins for tumour-targeting applications.
    Friedman M; Ståhl S
    Biotechnol Appl Biochem; 2009 May; 53(Pt 1):1-29. PubMed ID: 19341363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies as targeting and therapeutic agents: prospects for liver transplantation, hepatitis and hepatocellular carcinoma.
    Luk JM; Wong KF
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):482-8. PubMed ID: 16700883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development.
    Mascelli MA; Zhou H; Sweet R; Getsy J; Davis HM; Graham M; Abernethy D
    J Clin Pharmacol; 2007 May; 47(5):553-65. PubMed ID: 17379759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on therapeutic monoclonal antibodies.
    Bussel JB; Giulino L; Lee S; Patel VL; Sandborg C; Stiehm ER
    Curr Probl Pediatr Adolesc Health Care; 2007 Apr; 37(4):118-35. PubMed ID: 17434008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human antibodies by design.
    Vaughan TJ; Osbourn JK; Tempest PR
    Nat Biotechnol; 1998 Jun; 16(6):535-9. PubMed ID: 9624683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic monoclonal antibodies: trends in development and approval in the US.
    Reichert JM
    Curr Opin Mol Ther; 2002 Apr; 4(2):110-8. PubMed ID: 12044031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.
    Silva HM; Vieira PM; Costa PL; Pimentel BM; Moro AM; Kalil J; Maranhão AQ; Coelho V; Brigido MM
    Immunol Lett; 2009 Aug; 125(2):129-36. PubMed ID: 19573559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant antibodies: alternative strategies for developing and manipulating murine-derived monoclonal antibodies.
    Peterson NC
    Lab Anim Sci; 1996 Feb; 46(1):8-14. PubMed ID: 8699826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.